Trial Outcomes & Findings for Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration. (NCT NCT02481505)
NCT ID: NCT02481505
Last Updated: 2021-05-18
Results Overview
When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
COMPLETED
PHASE2
45 participants
Up to 5 hours after regression of two dermatomers
2021-05-18
Participant Flow
Participant milestones
| Measure |
3 mL Chloroprocaine HCl 1%
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Overall Study
STARTED
|
15
|
15
|
15
|
|
Overall Study
COMPLETED
|
15
|
15
|
15
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration.
Baseline characteristics by cohort
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
Total
n=45 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0.0 Participants
n=99 Participants
|
0.0 Participants
n=107 Participants
|
0.0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
15 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
45 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Continuous
|
41.0 years
STANDARD_DEVIATION 11.7 • n=99 Participants
|
39.4 years
STANDARD_DEVIATION 12.5 • n=107 Participants
|
41.5 years
STANDARD_DEVIATION 13.9 • n=206 Participants
|
40.6 years
STANDARD_DEVIATION 12.5 • n=7 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
18 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
27 Participants
n=7 Participants
|
|
Region of Enrollment
Italy
|
15 participants
n=99 Participants
|
15 participants
n=107 Participants
|
15 participants
n=206 Participants
|
45 participants
n=7 Participants
|
PRIMARY outcome
Timeframe: Up to 5 hours after regression of two dermatomersWhen Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Regression of Spinal Block
|
40.8 minutes
Standard Deviation 12.1
|
39.4 minutes
Standard Deviation 12.5
|
41.5 minutes
Standard Deviation 13.9
|
SECONDARY outcome
Timeframe: Up to 40 min after spinal injectionTime period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
|
5.4 minutes
Standard Deviation 3
|
6.6 minutes
Standard Deviation 3.4
|
4.8 minutes
Standard Deviation 2
|
SECONDARY outcome
Timeframe: Up to 40 min after spinal injectionTime period from spinal injection (time 0 h) to achievement of motor block
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Onset of Motor Block
|
6.3 minutes
Standard Deviation 3.2
|
6 minutes
Standard Deviation 3.3
|
4.4 minutes
Standard Deviation 2.3
|
SECONDARY outcome
Timeframe: Up to 40 min after spinal injectionTime period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Readiness for Surgery
|
8 minutes
Standard Deviation 4.1
|
7.9 minutes
Standard Deviation 4.7
|
5.3 minutes
Standard Deviation 2
|
SECONDARY outcome
Timeframe: Up to 1 h and 40 min after readiness for surgeryOutcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Regression of Spinal Block
|
1.761 hours
Standard Deviation 0.348
|
2.127 hours
Standard Deviation 0.457
|
2.229 hours
Standard Deviation 0.379
|
SECONDARY outcome
Timeframe: Up to 5 h after regression of two dermatomersTime period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Resolution of Sensory Block to S1(Min)
|
1.761 hours
Standard Deviation 0.348
|
2.127 hours
Standard Deviation 0.457
|
2.195 hours
Standard Deviation 0.386
|
SECONDARY outcome
Timeframe: Up to 5 h after regression of two dermatomersTime period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Resolution of Motor Block
|
2.662 hours
Standard Deviation 0.789
|
3.361 hours
Standard Deviation 1.120
|
3.213 hours
Standard Deviation 0.856
|
SECONDARY outcome
Timeframe: Up to 5 h after regression of two dermatomersTime period from spinal injection (time 0 h) to the time when the patient can walk unassisted
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Unassisted Ambulation
|
2.662 hours
Standard Deviation 0.789
|
3.361 hours
Standard Deviation 1.120
|
3.213 hours
Standard Deviation 0.856
|
SECONDARY outcome
Timeframe: Up to 5 h after regression of two dermatomersMetameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Sensory Block Metameric Level
T2
|
0 participants
|
2 participants
|
2 participants
|
|
Sensory Block Metameric Level
T3
|
1 participants
|
0 participants
|
1 participants
|
|
Sensory Block Metameric Level
T4
|
3 participants
|
2 participants
|
1 participants
|
|
Sensory Block Metameric Level
T6
|
0 participants
|
1 participants
|
4 participants
|
|
Sensory Block Metameric Level
T7
|
1 participants
|
0 participants
|
1 participants
|
|
Sensory Block Metameric Level
T8
|
3 participants
|
3 participants
|
2 participants
|
|
Sensory Block Metameric Level
T10
|
3 participants
|
1 participants
|
3 participants
|
|
Sensory Block Metameric Level
T12
|
3 participants
|
5 participants
|
1 participants
|
|
Sensory Block Metameric Level
L1
|
1 participants
|
1 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Up to 1 h and 40 min after readiness for surgeryMaximum metameric level of sensory block (decreased or absent sensation) achieved
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Maximum Level of Sensory Block
T7
|
1 participants
|
0 participants
|
1 participants
|
|
Maximum Level of Sensory Block
T8
|
3 participants
|
3 participants
|
2 participants
|
|
Maximum Level of Sensory Block
T10
|
3 participants
|
1 participants
|
3 participants
|
|
Maximum Level of Sensory Block
T12
|
3 participants
|
5 participants
|
1 participants
|
|
Maximum Level of Sensory Block
L1
|
1 participants
|
1 participants
|
0 participants
|
|
Maximum Level of Sensory Block
T2
|
0 participants
|
2 participants
|
2 participants
|
|
Maximum Level of Sensory Block
T3
|
1 participants
|
0 participants
|
1 participants
|
|
Maximum Level of Sensory Block
T4
|
3 participants
|
2 participants
|
1 participants
|
|
Maximum Level of Sensory Block
T6
|
0 participants
|
1 participants
|
4 participants
|
SECONDARY outcome
Timeframe: Up to 1 h and 40 min after readiness for surgeryTime period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Maximum Level of Sensory Block
|
0.224 minutes
Standard Deviation 0.14
|
0.235 minutes
Standard Deviation 0.077
|
0.234 minutes
Standard Deviation 0.098
|
SECONDARY outcome
Timeframe: Up to 5 h after regression of two dermatomersTime period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block
|
0.687 hours
Standard Deviation 0.361
|
0.851 hours
Standard Deviation 0.468
|
0.695 hours
Standard Deviation 0.290
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryTime period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Eligibility for Home Discharge
|
3.021 hours
Standard Deviation 1.012
|
3.545 hours
Standard Deviation 1.281
|
3.530 hours
Standard Deviation 0.887
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryTime period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to First Spontaneous Urine Voiding
|
2.530 hours
Standard Deviation 0.761
|
3.361 hours
Standard Deviation 1.120
|
3.067 hours
Standard Deviation 0.755
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryTime from spinal injection (time 0 h) to first post-operative analgesia
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to First Post-operative Analgesia
|
8.186 hours
Standard Deviation 10.815
|
2.928 hours
Standard Deviation 1.228
|
2.988 hours
Standard Deviation 1.167
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryOutcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Time to Administration of Rescue Anaesthesia or Rescue Analgesia
|
0.717 hours
Standard Deviation 0.397
|
0.315 hours
Standard Deviation 0.049
|
0 hours
Standard Deviation 0
|
SECONDARY outcome
Timeframe: at pre-dose, 5, 10, 30 and 60 min after spinal punctureOutcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
5 minutes post-dose
|
16.127 minutes
Standard Deviation 20.108
|
20.411 minutes
Standard Deviation 23.037
|
24.887 minutes
Standard Deviation 20.340
|
|
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
10 minutes post-dose
|
41.440 minutes
Standard Deviation 31.778
|
38.851 minutes
Standard Deviation 25.492
|
75.833 minutes
Standard Deviation 67.635
|
|
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
30 minutes post-dose
|
57.459 minutes
Standard Deviation 43.773
|
67.180 minutes
Standard Deviation 36.899
|
97.647 minutes
Standard Deviation 61.704
|
|
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
60 minutes post-dose
|
47.020 minutes
Standard Deviation 41.381
|
53.093 minutes
Standard Deviation 31.803
|
78.380 minutes
Standard Deviation 48.403
|
SECONDARY outcome
Timeframe: at the time of first urine voiding post surgeryTime period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine
|
1217.7 ng/mL
Standard Deviation 627.8
|
1827.9 ng/mL
Standard Deviation 904.1
|
2103.5 ng/mL
Standard Deviation 1537.5
|
SECONDARY outcome
Timeframe: Up to Day 6 +/- 1 after spinal punctureAll AEs occurring or worsening after the dose of IMP
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Treatment-emergent Adverse Events (TEAEs)
Procedural pain
|
14 participants
|
13 participants
|
13 participants
|
|
Treatment-emergent Adverse Events (TEAEs)
Injection site pain
|
2 participants
|
3 participants
|
3 participants
|
|
Treatment-emergent Adverse Events (TEAEs)
nausea
|
0 participants
|
1 participants
|
1 participants
|
|
Treatment-emergent Adverse Events (TEAEs)
diarrhea
|
0 participants
|
1 participants
|
0 participants
|
|
Treatment-emergent Adverse Events (TEAEs)
vomiting
|
0 participants
|
1 participants
|
0 participants
|
|
Treatment-emergent Adverse Events (TEAEs)
bradycardia
|
0 participants
|
1 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Up to Day 6 +/- 1 after spinal punctureOutcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Transient Neurological Symptoms (TNS)
day 2
|
0 participants
|
0 participants
|
0 participants
|
|
Transient Neurological Symptoms (TNS)
day 7
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Up to Day 6 +/- 1 after spinal punctureNumber of patients with pain at the site of injection and at the site of surgery
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Pain Assessment at the Site of Injection and at the Site of Surgery
Immediately after regression of spinal block
|
0 participants
|
0 participants
|
0 participants
|
|
Pain Assessment at the Site of Injection and at the Site of Surgery
discharge
|
0 participants
|
0 participants
|
0 participants
|
|
Pain Assessment at the Site of Injection and at the Site of Surgery
day 2
|
14 participants
|
15 participants
|
15 participants
|
|
Pain Assessment at the Site of Injection and at the Site of Surgery
day 7
|
15 participants
|
15 participants
|
15 participants
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryThe following normal ranges Heart Rate parameters will be used: 50-90 beats/min
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Heart Rate
screening
|
62.2 beats/min
Standard Deviation 8.5
|
67.5 beats/min
Standard Deviation 11.4
|
70.7 beats/min
Standard Deviation 8.6
|
|
Heart Rate
baseline
|
63.1 beats/min
Standard Deviation 9.4
|
71 beats/min
Standard Deviation 14
|
71.7 beats/min
Standard Deviation 9.2
|
|
Heart Rate
discharge
|
64.9 beats/min
Standard Deviation 7
|
66.9 beats/min
Standard Deviation 10
|
67 beats/min
Standard Deviation 8
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryThe following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Blood Pressure
Systolic Blood Pressure screening
|
120 mmHg
Standard Deviation 12.9
|
126 mmHg
Standard Deviation 21.74
|
121.6 mmHg
Standard Deviation 9.1
|
|
Blood Pressure
Systolic Blood Pressure baseline
|
116.9 mmHg
Standard Deviation 10.5
|
127.9 mmHg
Standard Deviation 19.7
|
125.5 mmHg
Standard Deviation 14.1
|
|
Blood Pressure
Systolic Blood Pressure discharge
|
116.9 mmHg
Standard Deviation 10.9
|
124.7 mmHg
Standard Deviation 14.7
|
121.7 mmHg
Standard Deviation 8.9
|
|
Blood Pressure
Diastolic Blood Pressure screening
|
81.5 mmHg
Standard Deviation 12.1
|
78.9 mmHg
Standard Deviation 11.9
|
80.5 mmHg
Standard Deviation 9.9
|
|
Blood Pressure
Diastolic Blood Pressure baseline
|
74.5 mmHg
Standard Deviation 10.3
|
79.8 mmHg
Standard Deviation 10.9
|
79.1 mmHg
Standard Deviation 13.3
|
|
Blood Pressure
Diastolic Blood Pressure discharge
|
75.5 mmHg
Standard Deviation 12.2
|
79 mmHg
Standard Deviation 8.1
|
82 mmHg
Standard Deviation 9.5
|
SECONDARY outcome
Timeframe: Expected up to 24 hrs post surgeryThe following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%
Outcome measures
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 Participants
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
SpO2
screening
|
99.7 percentage
Standard Deviation 0.96
|
99.13 percentage
Standard Deviation 1.25
|
98.53 percentage
Standard Deviation 1.36
|
|
SpO2
baseline
|
99.4 percentage
Standard Deviation 0.91
|
99.13 percentage
Standard Deviation 0.83
|
98.53 percentage
Standard Deviation 1.51
|
|
SpO2
discharge
|
99.33 percentage
Standard Deviation 0.72
|
99.33 percentage
Standard Deviation 0.90
|
99 percentage
Standard Deviation 1.07
|
Adverse Events
3 mL Chloroprocaine HCl 1%
4 mL Chloroprocaine HCl 1%
5 mL Chloroprocaine HCl 1%
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
3 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
4 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
5 mL Chloroprocaine HCl 1%
n=15 participants at risk
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Chloroprocaine HCl 1%: Intrathecal Route
|
|---|---|---|---|
|
Injury, poisoning and procedural complications
Procedural pain
|
93.3%
14/15 • Number of events 17 • 7 days
No SAEs and No subject discontinued for AEs
|
86.7%
13/15 • Number of events 20 • 7 days
No SAEs and No subject discontinued for AEs
|
86.7%
13/15 • Number of events 17 • 7 days
No SAEs and No subject discontinued for AEs
|
|
General disorders
injection site pain
|
13.3%
2/15 • Number of events 2 • 7 days
No SAEs and No subject discontinued for AEs
|
20.0%
3/15 • Number of events 3 • 7 days
No SAEs and No subject discontinued for AEs
|
20.0%
3/15 • Number of events 3 • 7 days
No SAEs and No subject discontinued for AEs
|
|
Gastrointestinal disorders
nausea
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
|
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
|
|
Gastrointestinal disorders
diarrhoae
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
|
Gastrointestinal disorders
vomiting
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
|
Cardiac disorders
bradycardia
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
6.7%
1/15 • Number of events 1 • 7 days
No SAEs and No subject discontinued for AEs
|
0.00%
0/15 • 7 days
No SAEs and No subject discontinued for AEs
|
Additional Information
Elisabetta Donati Clinical Project Leader
Sintetica SA, via Penate 5 Mendrisio
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place